SMR 2019: Lifileucel Therapy Leads to Durable Response in Heavily Pretreated, Refractory, Advanced Melanoma
Patients had received prior anti–PD-1/-L1 and BRAF/MEK inhibitors if they had BRAF-mutated melanoma.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.